← Back to Search

Protease Inhibitor

ALV003 for Celiac Disease

Phase 2
Waitlist Available
Research Sponsored by Alvine Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

To determine the effects of 12 weeks administration of different dose levels of ALV003 on the mucosal lining of the small intestine and symptoms in celiac disease patients.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy: Intestinal mucosal morphometry
Secondary outcome measures
Efficacy: Intestinal intraepithelial lymphocyte density
Safety: safety and tolerability of ALV003
Other outcome measures
Celiac disease-specific serology
Quality of life

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ALV003Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Latiglutenase
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Alvine Pharmaceuticals Inc.Lead Sponsor
6 Previous Clinical Trials
329 Total Patients Enrolled
6 Trials studying Celiac Disease
329 Patients Enrolled for Celiac Disease
Daniel Adelman, MDStudy DirectorAlvine Pharmaceuticals Inc.
1 Previous Clinical Trials
110 Total Patients Enrolled
1 Trials studying Celiac Disease
110 Patients Enrolled for Celiac Disease

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Florida
How old are they?
65+
What site did they apply to?
NCT01917630
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients
2013. "Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01917630.
All > Celiac Disease
~43 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top